Merit Medical Systems (MMSI) Projected to Post Quarterly Earnings on Thursday

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) will likely be announcing its Q1 2025 quarterly earnings data after the market closes on Thursday, April 24th. Analysts expect the company to announce earnings of $0.75 per share and revenue of $352.57 million for the quarter.

Merit Medical Systems Stock Performance

Shares of NASDAQ MMSI traded up $1.85 during mid-day trading on Tuesday, reaching $91.45. 642,896 shares of the company were exchanged, compared to its average volume of 487,333. Merit Medical Systems has a twelve month low of $72.81 and a twelve month high of $111.45. The company's 50-day simple moving average is $99.45 and its 200-day simple moving average is $100.57. The stock has a market capitalization of $5.40 billion, a P/E ratio of 44.83, a P/E/G ratio of 2.34 and a beta of 0.85. The company has a quick ratio of 3.82, a current ratio of 5.36 and a debt-to-equity ratio of 0.57.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on MMSI shares. Raymond James increased their price target on Merit Medical Systems from $105.00 to $110.00 and gave the company an "outperform" rating in a research note on Tuesday, December 31st. Wells Fargo & Company lowered their target price on shares of Merit Medical Systems from $120.00 to $117.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Piper Sandler restated an "overweight" rating and set a $116.00 price target (up from $114.00) on shares of Merit Medical Systems in a research report on Wednesday, January 29th. Barrington Research reissued an "outperform" rating and issued a $111.00 target price on shares of Merit Medical Systems in a research report on Friday, April 11th. Finally, JPMorgan Chase & Co. assumed coverage on Merit Medical Systems in a report on Friday, March 28th. They set an "overweight" rating and a $120.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $114.33.

Insider Buying and Selling at Merit Medical Systems

In other Merit Medical Systems news, Director Stephen C. Evans sold 5,000 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $105.31, for a total transaction of $526,550.00. Following the transaction, the director now directly owns 4,657 shares of the company's stock, valued at $490,428.67. This represents a 51.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Raul Jr. Parra sold 12,451 shares of the business's stock in a transaction on Friday, February 28th. The stock was sold at an average price of $98.81, for a total transaction of $1,230,283.31. Following the transaction, the chief financial officer now directly owns 24,201 shares in the company, valued at $2,391,300.81. This trade represents a 33.97 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 109,132 shares of company stock worth $11,139,521. 3.70% of the stock is currently owned by insiders.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.